Community Bank N.a. buys $1,844,346 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Community Bank N.a. scooped up 1,056 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 13, 2016. The investment management firm now holds a total of 45,006 shares of Abbott Laboratories which is valued at $1,844,346.Abbott Laboratories makes up approximately 0.43% of Community Bank N.a.’s portfolio.

Other Hedge Funds, Including , Msi Financial Services Inc boosted its stake in ABT in the latest quarter, The investment management firm added 4,189 additional shares and now holds a total of 78,826 shares of Abbott Laboratories which is valued at $3,230,289. Abbott Laboratories makes up approx 0.11% of Msi Financial Services Inc’s portfolio.Grassi Investment Management boosted its stake in ABT in the latest quarter, The investment management firm added 2,125 additional shares and now holds a total of 114,250 shares of Abbott Laboratories which is valued at $4,702,530. Abbott Laboratories makes up approx 0.91% of Grassi Investment Management’s portfolio.Hollencrest Securities reduced its stake in ABT by selling 5,470 shares or 26.2% in the most recent quarter. The Hedge Fund company now holds 15,407 shares of ABT which is valued at $634,152. Abbott Laboratories makes up approx 0.09% of Hollencrest Securities’s portfolio.Private Asset Management Inc reduced its stake in ABT by selling 110 shares or 0.86% in the most recent quarter. The Hedge Fund company now holds 12,608 shares of ABT which is valued at $538,866. Abbott Laboratories makes up approx 0.09% of Private Asset Management Inc’s portfolio.Lvm Capital Management Ltdmi boosted its stake in ABT in the latest quarter, The investment management firm added 30,674 additional shares and now holds a total of 64,149 shares of Abbott Laboratories which is valued at $2,741,728. Abbott Laboratories makes up approx 0.87% of Lvm Capital Management Ltdmi’s portfolio.

Abbott Laboratories closed down -2.34 points or -5.38% at $41.16 with 2,38,96,101 shares getting traded on Tuesday. Post opening the session at $43.2, the shares hit an intraday low of $41.02 and an intraday high of $43.27 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.